Denali Therapeutics (NASDAQ:DNLI) Trading Up 4.1% – What’s Next?

Denali Therapeutics Inc. (NASDAQ:DNLI) rose 4.1% during mid-day trading on Wednesday . The stock traded as high as $12.54 and last traded at $12.79. Approximately 35,969 shares were traded during trading, a decline of 97% from the average daily volume of 1,040,093 shares. The stock had previously closed at $12.29.

Analyst Ratings Changes

A number of equities analysts have commented on DNLI shares. Oppenheimer decreased their price target on Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating on the stock in a research note on Monday, March 3rd. Baird R W upgraded Denali Therapeutics to a “strong-buy” rating in a report on Tuesday, January 7th. HC Wainwright boosted their price objective on shares of Denali Therapeutics from $80.00 to $87.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Bank of America dropped their target price on shares of Denali Therapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, March 10th. Finally, William Blair restated an “outperform” rating on shares of Denali Therapeutics in a report on Friday, February 28th. Two analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Denali Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.20.

Denali Therapeutics Stock Down 6.9 %

The stock has a market cap of $1.86 billion, a PE ratio of -4.63 and a beta of 1.58. The stock’s fifty day moving average price is $18.27 and its 200 day moving average price is $22.84.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.08. On average, equities research analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Insider Buying and Selling at Denali Therapeutics

In related news, Director Steve E. Krognes sold 3,339 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total transaction of $69,484.59. Following the completion of the sale, the director now directly owns 25,757 shares in the company, valued at approximately $536,003.17. The trade was a 11.48 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Carole Ho sold 12,255 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $20.22, for a total transaction of $247,796.10. Following the completion of the transaction, the insider now owns 178,580 shares in the company, valued at $3,610,887.60. The trade was a 6.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 44,860 shares of company stock valued at $909,039. 7.90% of the stock is owned by company insiders.

Institutional Trading of Denali Therapeutics

Hedge funds have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company grew its stake in shares of Denali Therapeutics by 20.0% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 206,819 shares of the company’s stock valued at $6,025,000 after acquiring an additional 34,538 shares during the period. BNP Paribas Financial Markets raised its position in shares of Denali Therapeutics by 230.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 27,625 shares of the company’s stock valued at $805,000 after purchasing an additional 19,259 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Denali Therapeutics by 12.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,719 shares of the company’s stock worth $866,000 after buying an additional 3,316 shares during the period. Holocene Advisors LP increased its stake in Denali Therapeutics by 65.0% in the 3rd quarter. Holocene Advisors LP now owns 97,447 shares of the company’s stock worth $2,839,000 after buying an additional 38,405 shares in the last quarter. Finally, Polar Asset Management Partners Inc. raised its holdings in Denali Therapeutics by 70.5% during the third quarter. Polar Asset Management Partners Inc. now owns 41,100 shares of the company’s stock valued at $1,197,000 after acquiring an additional 17,000 shares during the period. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.